Get started
Author

Alasdair C. Macculloch

Observed names: A MacCulloch, A. MacCulloch, Alasdair C. MacCulloch, Alasdair MacCulloch, MacCulloch, Alasdair, Macculloch, A.C.
ORCID: 0000-0001-9904-9063
Observed ORCIDs: 0000-0001-9904-9063, 0009-0001-6786-1257
OpenAlex ID: A5055258723
The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations
2018 · Sorrel Burden, Matthew Hemstock, et al. · Clinical Nutrition ESPEN · 29
PDF
Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom
2023 · Lena Hubig, Anna-Katrine Sussex, et al. · Journal of health economics and outcomes research · 13
Burden associated with Fabry disease and its treatment in 12–15 year olds: results from a European survey
2022 · Lisa Bashorum, Gerard McCaughey, et al. · Orphanet Journal of Rare Diseases · 12
PDF
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data
2024 · Simon Shohet, Noemi Hummel, et al. · Journal of Comparative Effectiveness Research · 11
Synthesis and hydrolytic stability of the α and β anomers of 4′-thio-2′-deoxyuridine and their 5-substituted analogs. Competition between the acid-catalysed depyrimidination and isomerisation to a 5-thiopyranoside nucleoside
1998 · Graham P. Otter, Mohamed I. Elzagheid, et al. · Journal of the Chemical Society Perkin Transactions 2 · 9
Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment
2016 · Andrew J. Lloyd, Katy Gallop, et al. · Current Medical Research and Opinion · 8
PDF
A novel method for deuteration of 2′-deoxy-4′-thionucleosides
1998 · Alasdair C. MacCulloch, Richard T. Walker · Tetrahedron · 6
Systematic Literature Review of Health-Related Quality of Life In Patients Receiving Parenteral Nutrition
2015 · C Neves, A Chapman, et al. · Value in Health · 4
Exploring Quality of Life in Adults Living With Late-onset Pompe Disease: A Combined Quantitative and Qualitative Analysis of Patient Perceptions from Australia, France, Italy, and the Netherlands
2025 · Holly Lumgair, Lisa Bashorum, et al. · Journal of health economics and outcomes research · 3
PDF
POSA329 Fabry Disease: Symptom Burden, Health-Related Quality of Life Burden and Treatment Satisfaction
2022 · K Gallop, A Lloyd, et al. · Value in Health · 1
Asymmetric Michael Reactions Using Tartrate-based Magnesium Catalysts
2002 · Richard F. Jackson, Alasdair C. MacCulloch, et al. · Synlett · 1
5-Methyl-2′-deoxy-4′-thio-α-uridine (R)-S-oxide
2000 · Ming Sun, Alasdair C. Macculloch, et al. · Acta Crystallographica Section C Crystal Structure Communications · 1
5-Ethyl-2′-deoxy-4′-thiouridine (R)-S-oxide monohydrate
2000 · Ming Sun, Alasdair C. Macculloch, et al. · Acta Crystallographica Section C Crystal Structure Communications · 1
Migalastat Versus Enzyme Replacement Therapy in Treatment‐Naïve F abry Disease: Real‐World Evidence From the followME F abry Pathfinders Registry
2026 · Peter Nordbeck, Agnieszka Kopiec, et al. · Journal of Inherited Metabolic Disease
PDF
A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa
2026 · Amy Dymond, Will Green, et al. · Journal of Comparative Effectiveness Research
Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data
2026 · Shuai Fu, Noemi Hummel, et al. · Journal of Comparative Effectiveness Research
Real-world effectiveness of migalastat versus enzyme replacement therapy in previously treatment-naïve patients with Fabry disease: Analyses of matched populations from the global followME Pathfinders registry
2026 · Peter Nordbeck, Agnieszka Kopiec, et al. · Molecular Genetics and Metabolism
Matching-adjusted indirect comparisons (MAICs) and network meta-analyses (NMAs) of the oral small-molecule chaperone migalastat versus intravenous enzyme replacement therapies (ERTs) for clinical measures in Fabry disease
2026 · Vera Gielen, Agnieszka Kopiec, et al. · Molecular Genetics and Metabolism
SA65 Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
2025 · Noemi Hummel, Agnieszka Kopiec, et al. · Value in Health
MSR2 A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa
2025 · Amy Dymond, William Green, et al. · Value in Health
225PPompe disease in Sweden: a real-world evidence study of disease burden, treatment patterns for enzyme replacement therapy and concomitant medications
2025 · A. Ekström, M. Stelmaszuk, et al. · Neuromuscular Disorders
EE215 Pompe Disease in Sweden: A Real-World Evidence Study Investigating Healthcare Resource Utilisation and Costs
2025 · Alasdair MacCulloch, Sofia Nordin, et al. · Value in Health
Pompe disease in Sweden: A real-world evidence study investigating disease burden, treatment patterns for enzyme replacement therapy and concomitant medications
2025 · Sofia Nordin, Natalia M. Stelmaszuk, et al. · Molecular Genetics and Metabolism
PCR137 The Impact of Patient Perception of Disease Progression on Health-Related Quality of Life (HRQoL) in Late-Onset Pompe Disease
2024 · H. Lumgair, A. MacCulloch, et al. · Value in Health
PDF
EE401 A Comparison of Health State Occupancy Between Cipaglucosidase Alfa/Miglustat and Alglucosidase Alfa Within a Cost-Effectiveness Modelling Analysis of Late-Onset Pompe Disease
2023 · S. Raza, A. Dymond, et al. · Value in Health
PDF
Works count: 43
Citation count: 99
H-index: 6
I10-index: 4
Year
Topic
Type